“DUR-928- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Alcoholic Hepatitis in 7 Major Markets. A detailed picture of the DUR-928 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
DUR-928 is the lead product candidate in DURECT’s Epigenetic Regulator program. It is an endogenous, orally bioavailable small molecule that has been shown in nonclinical studies to modulate the activity of nuclear receptors playing an important regulatory role in cellular functions such as lipid homeostasis, inflammation, and cell survival. DUR-928 is a sulfated oxysterol—representing a new class of therapeutics with a novel mechanism of action. DUR-928 epigenetically modifies gene activity without changing the DNA sequence itself.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of DUR-928 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of DUR-928 covering trial interventions, trial conditions, trial status, start and completion dates.
1. Drug Overview
1.1. Product Detail
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Research and development activity
1.4.1. Clinical Development
1.4.2. Safety and Efficacy
1.5. Other Development Activities
2. Market Assesment
2.1. 7MM Market Analysis
2.2. The United States Market
2.3. Germany Market
2.4. France Market
2.5. Italy Market
2.6. Spain Market
2.7. United Kingdom Market
2.8. Japan Market
3. SWOT Analysis
4. Analyst Views
5. Market Competitors
6. Other Emerging Therapies
7. Appendix
8. Report Purchase Options
List of Table
Table 1 DUR-928, Description
Table 2 DUR-928, Clinical Trial Description
Table 3 DUR-928, 7MM Market Size from 2020 to 2030 (in Million USD)
Table 4 Market Competitors
Table 5 Other Emerging Therapies
List of Figures
Figure 1 The Development Timeline of DUR-928
Figure 2 Patent Details, DUR-928
Figure 3 DUR-928, 7MM Market Size from 2020 to 2030 (in Million USD)
Figure 4 DUR-928, US Market Size from 2020 to 2030 (in Millions USD)
Figure 5 DUR-928, EU5 Market Size from 2020 to 2030 (in Millions USD)
Figure 6 DUR-928, Japan Market Size from 2020 to 2030 (in Millions USD)
